SCHEMBL20889705

SCHEMBL20889705

COC(=O)c1cccc(Nc2c(-c3c(O)ccc4ccccc34)nc3cnccn23)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SALL4 Q9UJQ4 12/20 1.00
SYK P43405 1/20 0.54
GAA P10253 5/20 0.53
MAPT P10636 5/20 0.53
KDM4E B2RXH2 3/20 0.53
ALDH1A1 P00352 3/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
MEN1 O00255 2/20 0.53
MAPK1 P28482 2/20 0.53
KMT2A Q03164 2/20 0.53
LMNA P02545 1/20 0.53
HSD17B10 Q99714 1/20 0.53
HPGD P15428 2/20 0.46
TUBB4A P04350 2/20 0.46
TUBB P07437 2/20 0.46
TUBA3C P0DPH7 2/20 0.46
TUBA1B P68363 2/20 0.46
TUBA4A P68366 2/20 0.46
TUBB4B P68371 2/20 0.46
TUBB3 Q13509 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20889697 0.89 SALL4 (0.81) SALL4MAPTMEN1KMT2ATUBB4A
SCHEMBL20889322 0.88 SALL4 (0.81) SALL4GAAMAPTKDM4EALDH1A1
SCHEMBL20889570 0.84 SALL4 (0.72) SALL4SYKGAAMAPTKDM4E
SCHEMBL2923992 0.84 SALL4 (0.71) SALL4SYKGAAMAPTKDM4E
SCHEMBL31355261 0.84 SALL4 (0.71) SALL4SYKGAAMAPTKDM4E
SCHEMBL20889728 0.83 SALL4 (1.00) SALL4GAAMAPTKDM4EALDH1A1
SCHEMBL31355404 0.82 MAPT (0.77) SALL4SYKGAAMAPTKDM4E
SCHEMBL31355323 0.82 SALL4 (0.69) SALL4SYKGAAMAPTKDM4E
SCHEMBL31355335 0.82 SALL4 (0.69) SALL4SYKGAAMAPTKDM4E
SCHEMBL31355390 0.81 SYK (0.81) SALL4SYKGAAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11530209-B2 Small molecule inhibition of transcription factor SALL4 and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-12-20 US disclosed
US-20200317664-A1 SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-10-08 US disclosed
WO-2019070943-A1 SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11530209-B2 Small molecule inhibition of transcription factor SALL4 and uses thereof SALL4, GLI2, TCF4 SALL4 1/4885SYK 3150/4885GAA 3761/4885
US-20200317664-A1 SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF SALL4, GLI2, TCF4 SALL4 1/4885SYK 3150/4885GAA 3761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.